JPMorgan reinstated coverage of Alkermes with a Neutral rating and $33 price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALKS:
- Alkermes raises FY23 adjusted EPS view to $1.57-$1.75 from $1.34-$1.57
- Alkermes completes separation of oncology business
- Alkermes management to meet with Piper Sandler
- Alkermes: SEC declares Form 10 registration statement filed by Mural effective
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call